The S protein of SARS-CoV-2 was chosen as a promising target by the majority of COVID-19 vaccines because blocking the interaction between the RBD of echinocandin and human angiotensin-converting enzyme 2 (ACE2) is effective in preventing infection [66,67]. This evidence concerns the gene PROS1 and COVID-19.